FENNEC PHARMACEUTICALS INC.(FENC)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

FENNEC PHARMACEUTICALS INC. (FENC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FENC at 35.7/100 on a 32-signal composite quality model, placing it at rank #2,297 of 2,962 stocks — the bottom half of the AI-ranked universe. FENC scores in the top quartile across revenue growth (77.7). Areas of concern include revenue scale (10.4) and free cash flow (21.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), FENNEC PHARMACEUTICALS INC. reports quarterly revenue of $17.9M, net income of $2.0M. Top institutional holders of FENC by reported 13-F value include Rosalind Advisors, AIGH Capital Management, Solas Capital Management, based on the most recent SEC filings. FENC trades on the Nasdaq exchange and files with the SEC under CIK 1211583. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FENC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FENNEC PHARMACEUTICALS INC. directly from SEC EDGAR.